Molecular Psychiatry · 2017 · 105 citations · 41 references
MedicineNeurologyNeuroscienceDementiaDiagnostic ImagingNeuroradiologyAlzheimer DiseaseBrain ImagingCognitive ImpairmentDementia BiomarkersNeurodegenerative DiseasesTau PathologyAlzheimer Disease DementiaAlzheimer Disease Tau PathologyAmyloid Pet ImagingCorticobasal SyndromePositron Emission Tomography DiagnosisPositron Emission Tomography QuantificationTau HyperphosphorylationTau Uptake
The development of tau-specific positron emission tomography (PET) tracers allows imaging in vivo the regional load of tau pathology in Alzheimer’s disease (AD) and other tauopathies. Eighteen patients with baseline investigations enroled in a 17-month follow-up study, including 16 with AD (10 had mild cognitive impairment and a positive amyloid PET scan, that is, prodromal AD, and six had AD dementia) and two with corticobasal syndrome. All patients underwent PET scans with [18F]THK5317 (tau deposition) and [18F]FDG (glucose metabolism) at baseline and follow-up, neuropsychological assessment at baseline and follow-up and a scan with [11C]PIB (amyloid-β deposition) at baseline only. At a group level, patients with AD (prodromal or dementia) showed unchanged [18F]THK5317 retention over time, in contrast to significant decreases in [18F]FDG uptake in temporoparietal areas. The pattern of changes in [18F]THK5317 retention was heterogeneous across all patients, with qualitative differences both between the two AD groups (prodromal and dementia) and among individual patients. High [18F]THK5317 retention was significantly associated over time with low episodic memory encoding scores, while low [18F]FDG uptake was significantly associated over time with both low global cognition and episodic memory encoding scores. Both patients with corticobasal syndrome had a negative [11C]PIB scan, high [18F]THK5317 retention with a different regional distribution from that in AD, and a homogeneous pattern of increased [18F]THK5317 retention in the basal ganglia over time. These findings highlight the heterogeneous propagation of tau pathology among patients with symptomatic AD, in contrast to the homogeneous changes seen in glucose metabolism, which better tracked clinical progression.
41
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Ronald C. Petersen, Glenn E. Smith, Stephen C. Waring et al. · Archives of Neurology · 1999 · 9K citations
Medicine, Neurology, Psychiatry +17
Kristopher J. Preacher, Patrick J. Curran, Daniel J. Bauer · Journal of Educational and Behavioral Statistics · 2006 · 5K citations
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois, Howard Feldman, Claudia Jacova et al. · The Lancet Neurology · 2014 · 3.3K citations · Full text